I am here to add my voice to the calls for action, support the More Time to Live campaign, and pay tribute to Breast Cancer Now.

Discussed the realities and myths surrounding secondary breast cancer, highlighting its incurability and the importance of accurate terminology. Acknowledged the need for better data collection to understand patient numbers and improve services. Called for progress on developing world-class research facilities and access to new drugs through NICE criteria changes.

Caroline Johnson congratulated MPs on securing the debate and praised Ashley Dalton's speech. She highlighted the uncertainty around data for secondary breast cancer, calling for an update on data collection from 2026 and asking how frequently it would be published. She inquired about plans to expand screening services, workforce needs, and genetic testing availability. Johnson also raised concerns about the reorganisation of integrated care boards due to budget cuts and NHS England's abolition under the Health Bill, questioning if this is slowing progress on the cancer plan. She asked for updates on research funding for lobular breast cancer and discussed issues facing hospices regarding national insurance contributions and staff shortages.

She highlighted that secondary breast cancer is the leading cause of death for women aged 40 to 49 in the UK, with around 1,000 people losing their lives each month. Helen called for better data collection and publication on secondary breast cancer cases to ensure accurate assessment of needs and appropriate planning of services. She noted that over 23% of respondents had to see their GP three or more times before diagnosis, while only 53% received sufficient information about clinical trials.

Each month in the UK, around 1,000 people die from secondary breast cancer, which equates to one life every 45 minutes. The drug Enhertu is available in Scotland and other European countries but not in England, Wales or Northern Ireland. There are also significant wait times for urgent referrals in Northern Ireland with only 6.8% seen within the 14-day target.

Mr Milne highlighted the lack of data and research on secondary lobular breast cancer, which affects 22 people daily in the UK. He noted that this form of cancer often goes undetected due to its unique growth patterns and is under-researched compared to ductal breast cancer. Mr Milne also emphasised the importance of dedicated treatment pathways and called for £20 million over five years for research into lobular breast cancer, which currently relies on medications designed for other cancers costing up to £3,000 per month.

Mary Foy highlighted the importance of secondary breast cancer data collection and accurate recording across the country. She raised concerns about inconsistencies in treatment access, particularly with NICE's assessment methods for life-extending treatments like Enhertu. Foy also praised hospice support but noted that one-third of people do not receive end-of-life care needs. She called on the Government to ensure consistent data collection, patient access to named contacts, and equitable treatment availability.

She thanked the hon. Member for West Lancashire and congratulated her colleagues on securing the debate, sharing her personal experience with breast cancer. Wendy highlighted the specific challenges of lobular breast cancer, noting that 22 people are diagnosed daily but may not be detected by standard tests. She called for dedicated research funding of £20 million over five years and urged devolved governments to contribute as well.